arvinas_logoART_lg.jpg
Arvinas to Present at Upcoming Investor Conferences
March 04, 2022 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., March 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas logo.jpg
Arvinas Reports First Quarter 2020 Financial Results and Provides a Corporate Update
April 28, 2020 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., April 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 16, 2020 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., March 16, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...